TSLP and asthma: Tezepelumab, a monoclonal antibody blocking TSLP, is currently in clinical trials for asthma (ClinicalTrials.gov identifiers NCT02054130 and NCT02698501) and atopic dermatitis (ClinicalTrials.gov identifier NCT02525094)12.